Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms

Xiang Zhou, Julia Mersi, Christine Riedhammer, Maximilian J. Steinhardt, Max Bittrich, Stefan Knop, Hermann Einsele, Leo Rasche, Klaus Martin Kortüm, Johannes M. Waldschmidt

Therapeutic Advances in Hematology

Published online on February 28, 2026

Abstract

Therapeutic Advances in Hematology, Volume 17, January-December 2026.
Background:Ixazomib is an oral proteasome inhibitor for relapsed/refractory multiple myeloma (RRMM). Our study aimed to analyze the efficacy and tolerability of ixazomib-based combination therapies.Methods:We performed a single-center retrospective ...